Atherosclerosis and Hyperlipidemia Research

Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.

Atherosclerosis and Hyperlipidemia Research Products Targets

Products for Atherosclerosis and Hyperlipidemia Research - Page 18

Cat.No. Product Name Information/Activity
BCC7207 U 46619 U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist.
BCC1332 AH 6809 AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.
BCC7961 GW 627368 GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.
BCC7393 L-161,982 L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.
BCC7156 L-655,240 103253-15-2
BCC5857 L-670,596 121083-05-4
BCC7654 L-798,106 L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM at EP4, EP1 and EP2, respectively.
BCC1822 ONO-AE3-208 High affinity and selective EP<sub>4</sub> antagonist,ONO-AE3-208 is an <b>EP4</b> antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
BCC6299 PF 04418948 PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.
BCC6968 SC 19220 19395-87-0